cancer

Early clinical data validate rare immune cell for Adicet’s off-the-shelf cancer therapy

Adicet Bio makes its therapies from gamma delta T cells, a rare type of immune cell that the company believes offer advantages compared to other cell therapies. The company now has early Phase 1 data that bring some validation to the approach.

Learn More Than 97% of Doctors About Lead-Time Bias

After reading this, you’ll know more than an estimated 97 percent of doctors about a critical concept called lead-time bias.  While running for president of the United States, former New York mayor Rudy Giuliani ran a campaign ad contrasting his 82 percent chance of surviving prostate cancer in the United States with the 44 percent …

Learn More Than 97% of Doctors About Lead-Time Bias Read More »

FDA turns down BeyondSpring chemo complication drug, asks for another trial

BeyondSpring Pharmaceuticals said the FDA wants another clinical trial to demonstrate patient benefit for its drug, a small molecule developed to treat a dangerous and life-threatening complication of chemotherapy. Shares of the biotech plunged more than 60% after the FDA’s complete response letter was announced.

Curie Therapeutics unveils $75M to widen scope of radiopharmaceuticals for cancer

Radiopharmaceuticals deploy radiation to damage cancer DNA, but Curie Therapeutics sees these therapies opening the door to a wider range of ways to kill tumors. The startup has raised $75 million in Series A financing to advance its research.

Patient death prompts clinical trial pause for Kura Oncology leukemia drug

The FDA placed a partial clinical hold on a Kura Oncology leukemia drug following the death of one patient in the early-stage study. Kura executives said the death may be related to differentiation syndrome, a known complication of leukemia therapies.

It Takes a Team: A Doctor With Terminal Cancer Relies on a Close-Knit Group in Her Final Days

The decisions have been gut-wrenching. Should she try another round of chemotherapy, even though she barely tolerated the last one? Should she continue eating, although it’s getting difficult? Should she take more painkillers, even if she ends up heavily sedated? Dr. Susan Massad, 83, has been making these choices with a group of close friends …

It Takes a Team: A Doctor With Terminal Cancer Relies on a Close-Knit Group in Her Final Days Read More »

FDA hands out approvals to Takeda transplant drug, Aadi Bio cancer therapy

Takeda Pharmaceutical won FDA approval for Livtencity, an antiviral developed to treat cytomegalovirus infection in transplant patients. The agency also approved an Aadi Biosciences drug, making it the first therapy authorized for treating a rare type of soft-tissue cancer.

Does Cell Phone Radiation Affect Fertility?

What is the effect of cell phone radiation on sperm motility and DNA damage? “Are men talking their reproductive health away?” There have been “unexplained declines in semen quality reported in several countries.” Might cell phones be playing a role? “Radio-frequency electromagnetic radiation (RF-EMR) from these devices could potentially affect sperm development and function.” The …

Does Cell Phone Radiation Affect Fertility? Read More »

Did the Oncology Care Model produce cost savings?

The answer is ‘yes’, but the magnitude of these savings are relatively small and more than offset by additional OCM program costs. Keating et al. (2021) writes: In this exploratory difference-in-differences study of Medicare fee-for-service beneficiaries with cancer undergoing chemotherapy (483 310 beneficiaries with 987 332 episodes treated at 201 OCM participating practices and 557 354 beneficiaries with …

Did the Oncology Care Model produce cost savings? Read More »

Overtreatment of Ductal Carcinoma In Situ

Nine out of ten women don’t realize that some breast cancers would never have caused any problems or even become known in one’s lifetime. This is an issue ductal carcinoma in situ has brought to the forefront. The whole point of cancer screening is to “detect life-threatening disease at an earlier, more curable stage. Effective …

Overtreatment of Ductal Carcinoma In Situ Read More »

FDA approves PharmaEssentia interferon drug for a rare type of blood cancer

Polycythemia vera, a rare blood cancer characterized by the overproduction of red blood cells, now has its first FDA-approved drug treatment. The agency awarded the regulatory nod to a PharmaEssentia drug that reduces the levels of those blood cells.

Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

Shots: Gaeta to receive $0.2M up front and is eligible to receive ~$7.5M in clinical and regulatory milestones based on product and indication The agreement will expand Oncorus’ clinical development of ONCR-177 for the treatment of cancer patients in combination with pembrolizumab and other immunotherapies, and also helps to bolster the commercialization strategy of the …

Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer Read More »

Notable Labs Launches by Acquiring Rights to Volasertib – Will Use Data, AI to Fast-Track Cancer Treatment

Thomas Bock, M.D., Chief Executive Officer of Notable What You Should Know: – Coming out of stealth, Notable Labs, a pioneer and developer of predictive precision medicines, is acquiring worldwide development and commercial rights to volasertib, a PLK-1 inhibitor in acute myeloid leukemia (AML) from Oncoheroes. – Notable will leverage its high-fidelity Predictive Precision Medicines Platform to identify …

Notable Labs Launches by Acquiring Rights to Volasertib – Will Use Data, AI to Fast-Track Cancer Treatment Read More »

Millions of Years of Healthy Life Lost Due to Cannabis

Every year, cannabis is estimated to result in two million years of healthy life lost due to disability. How much is that compared with alcohol and tobacco? “The popular notion seems to be that marijuana is a harmless pleasure,” but what are the potential adverse effects of marijuana use? That’s not an easy question to …

Millions of Years of Healthy Life Lost Due to Cannabis Read More »

Biotech startup Marengo unveils $80M and a new way to get T cells to fight cancer

Apple Tree Partners’ latest cancer biotech company, Marengo Therapeutics, is using antibodies to selectively activate T cells to fight cancer. Led by former Merck KGaA executive Zhen Su, the startup is launching with $80 million in financing, which will support a drug pipeline that includes a lead program expected to reach the clinic in 2022.

Biologics manufacturing drives Evotec’s $435M U.S. stock market debut

Evotec is an old player in the life sciences, but in offering new shares on the Nasdaq, the Germany-based company plans to bolster its new biologics manufacturing capabilities in the U.S and Europe. In other stock market debuts, IO Biotech’s IPO raised $100 million as it prepares a pivotal test of its lead cancer immunotherapy.

Those Who Claim the Greatest Benefit From Mammograms May Ironically Suffer the Most Harm

The mammogram paradox is that women who are harmed the most, are the ones who claim the greatest benefit. While false-positive results, pain during the procedure, and radiation exposure may be among the most frequent harms associated with mammogram screening, overdiagnosis “is now recognized as the most serious downside of population breast screening.” Overdiagnosis is …

Those Who Claim the Greatest Benefit From Mammograms May Ironically Suffer the Most Harm Read More »

Shoreline Biosciences secures $140M for off-the-shelf NK cell therapies for cancer

Gilead Sciences and BeiGene, which started research alliances with Shoreline Biosciences earlier this year, are among the investors in the biotech’s latest financing. The preclinical-stage company technology develops cell therapies for cancer by using natural killer cells.

How Much Cancer Do Mammograms Cause?

What is the risk-benefit ratio of the cancers picked up by mammograms and the cancers caused by mammograms? Over the last few decades, our radiation exposure has nearly doubled, due almost exclusively to medical sources, such as CT scans. While we’ve known that higher dose radiation from CT scans and angiograms, for example, can cause …

How Much Cancer Do Mammograms Cause? Read More »

Using bispecific antibodies to advance cancer immunotherapy

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Bispecific antibodies (bsAbs) are designed to recognise two different epitopes and, compared to current monovalent antibody therapeutics, bsAbs have enhanced binding, specificity, and efficacy, making them exciting candidates for more targeted cancer treatments. In 2019, there were …

Using bispecific antibodies to advance cancer immunotherapy Read More »

Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China

Shots: The companies collaborated to evaluate the safety, PK, PD & preliminary efficacy of the combination therapy of Innovent’s sintilimab + NeoCura’s NEO_PLIN2101 in patients with cancer The collaboration will bolster the clinical development of combination immunotherapy for multiple solid tumors & the companies plan to submit an IND application to the NMPA imminently Innovent …

Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China Read More »

Do Mammograms Have to Be Painful?

Excessive breast compression during mammography may not improve image quality and can cause unnecessary pain.  False-positive results have been described as “the most frequent harm” associated with mammogram screening, but it actually may be the pain. “There is a wide variation both in the reported frequency of pain and in degree of pain felt by …

Do Mammograms Have to Be Painful? Read More »

Xilio, Ventyx IPOs raise $269M to fuel plans to compete with big pharma drugs

Cancer drug developer Xilio Therapeutics and Ventyx Biosciences, a company with drug candidates in cancer and autoimmune diseases, are the latest life science companies to go public. They’ll use proceeds from their respective IPOs to continue clinical development of drugs being positioned as competitors to drugs from big pharmaceutical companies.

Already allied with Takeda, Egle raises €40M for its ‘starving’ immunotherapy

In less than two years, Egle Therapeutics launched, partnered with Takeda Pharmaceutical, and found its first cancer targets. Now the startup has €40M in Series A financing to further develop its new approach to modulating regulatory T cells as a way of treating autoimmune diseases and cancer.

Hackensack Meridian Health deploys Google Chrome OS devices, uses Cloud AI for screenings

The New Jersey-based health system initially partnered with Google in 2019. It has now migrated to Google Workspace, providing thousands of Chrome OS devices to remote workers, and is using Google Cloud AI capabilities to detect diseases like breast cancer and Covid-19.

Most Women May Experience at Least One False-Positive Mammogram

Odds are most women will get at least one false-positive mammogram, but, thankfully, most women who are called back for further testing of a suspicious mammogram finding do not end up having cancer after all.  In response to the Swiss Medical Board’s recommendation against women of any age getting routine mammograms, critics suggested that instead …

Most Women May Experience at Least One False-Positive Mammogram Read More »

Tentarix Bio unveils $50M for biologics with multiple functions, multiple targets

Biotech startup Tentarix Biotherapeutics has come out of stealth with $50 million and technology that develops biologic drugs endowed with multiple functions. The company aims to develop new multispecific biologic drugs for cancer and autoimmune diseases.

How Is It Possible That Mammograms Don’t Actually Save Lives?

For every life saved by mammography, as many as two to ten women are overdiagnosed and unnecessarily turned into breast cancer patients with all of the attendant harms of chemo, radiation, or surgery, without the benefits. What was the impact of the 2009 shift in recommendations by the U.S. Preventive Services Task Force (USPSTF) to …

How Is It Possible That Mammograms Don’t Actually Save Lives? Read More »

Untapped Opportunities for Oncology Medical Affairs Striving for better access and more equitable cancer care in communities nationwide

Pharmaceutical companies’ traditional medical education model relies on prominent researchers and publishers in the oncology space, otherwise known as Key Opinion Leaders (KOLs), to spread information about the newest therapies. There remain, however, significant untapped opportunities for oncology medical affairs to penetrate communities and reach more practitioners nationwide. Medical Science Liaisons that currently focus their …

Untapped Opportunities for Oncology Medical Affairs Striving for better access and more equitable cancer care in communities nationwide Read More »

Next Generation CAR-TCR Summit

The cell therapy field is showing no signs of slowing down, with huge investment and excitement around next generation products and their clinical validation in solid tumour indications. Formerly CAR-TCR Europe, the new and improved Next Generation CAR-TCR Therapies Summit is now the only industry-dedicated forum focused on the 2.0, next generation innovations in cell therapies. This year, we’ll be specifically focusing …

Next Generation CAR-TCR Summit Read More »

Why Doctors Should Not Encourage Breast Self-Exams

Various health organizations offer clashing mammogram recommendations that range from annual mammograms starting at age 40 to eliminating routine mammograms altogether. Who can you trust? Clashing mammogram recommendations ranging from annual mammograms starting at age 40 to eliminating routine mammograms altogether are offered by various health organizations. It’s hard to know who to trust given …

Why Doctors Should Not Encourage Breast Self-Exams Read More »

Exo Therapeutics adds $78M as cancer, inflammation drugs march toward clinic

Biotech startup Exo Therapeutics aims to overcome the challenges of drugging proteins by targeting exosites, locations that modulate enzyme activity. The company has four small molecule drug candidates for cancer and inflammation, and the company plans to use the $78 million in new financing to advance them toward human testing.

Anji Pharma adds $70M for clinical trials, expansion of ‘hub and spoke’ biz model

Cross-border biotech Anji Pharma closed $70 million in Series B funding to advance a drug pipeline that includes metabolic and cancer drugs. The biotech’s business model of finding promising drugs and forming subsidiaries to develop them is similar to approaches taken by Roivant Sciences and BridgeBio Pharma, among others.

Why Are Mammogram Guidelines Conflicting? 

When women are fully informed about the risks and benefits of mammograms, 70 percent may choose not to get screened. You may be in that 30 percent who opts to get a mammogram and absolutely have the right to decide for yourself.  “For nearly a century, public health organizations, professional associations, patient advocacy groups, academics, and clinicians largely viewed cancer screening as a simple, …

Why Are Mammogram Guidelines Conflicting?  Read More »

England’s cancer therapy backlog ‘could take more than a decade to shift’

A new report has suggested it could take until 2033 to clear the backlog of cancer treatment in England caused by the pandemic. The analysis by the Institute for Public Policy Research (IPPR) and Carnall Farrar (CF) consultancy suggests that timeline will be the result if hospitals can operate at a level 5% above what …

England’s cancer therapy backlog ‘could take more than a decade to shift’ Read More »

Seagen, Genmab antibody drug conjugate gets FDA approval in cervical cancer

The Seagen and Genmab antibody drug conjugate (ADC), named Tivdak, is approved to treat cases of cervical cancer that have returned or spread following treatment with chemotherapy. Tivdak is Seagen’s third ADC; for Genmab, the drug will become its first commercialized product.

90% of Women Appear Misinformed About Mammograms 

Most women are just being told what to do, rather than being given the facts needed to make a fully informed decision.   “Selling cancer screening can be easy,” begins an editorial in the Journal of the National Cancer Institute. “Induce fear by exaggerating risk. Offer hope by exaggerating the benefit of screening. And don’t mention harms [caused by the screening]. It is especially easy …

90% of Women Appear Misinformed About Mammograms  Read More »

Covid-Overwhelmed Hospitals Postpone Cancer Care and Other Treatment

It’s a bad time to get sick in Oregon. That’s the message from some doctors, as hospitals fill up with covid-19 patients and other medical conditions go untreated. Charlie Callagan looked perfectly healthy sitting outside recently on his deck in the smoky summer air in the small Rogue Valley town of Merlin, in southern Oregon. …

Covid-Overwhelmed Hospitals Postpone Cancer Care and Other Treatment Read More »

Takeda therapy gets speedy FDA nod for lung cancers with rare genetic signature

Takeda Pharmaceutical drug mobocertinib was approved by the FDA to treat non-small cell lung cancer in patients whose tumors carry a rare genetic signature. With the approval, Takeda can offer an oral alternative to a recently approved Johnson & Johnson drug that targets the same mutation but is given as an infusion.

Lead Contamination in Calcium Supplements 

Do calcium citrate and calcium carbonate have as much lead as calcium supplements derived from dolomite and animal bone?  You may remember I’ve explored the role calcium supplements may play in reducing lead exposure during pregnancy and breastfeeding, but that assumes the supplements themselves are not contaminated. Supplements with lead?  It all started with an extraordinary case report published in 1977, entitled “Lead-Contaminated Health Food.” As I discuss in my video Lead in Calcium …

Lead Contamination in Calcium Supplements  Read More »

The Effects of Nutritional Yeast for Cancer 

How can the beta glucan fiber in brewer’s, baker’s, and nutritional yeast improve wound healing and, potentially, anti-cancer immunity?  My video Benefits of Nutritional Yeast for Cancer opens with an image of an article titled “The Treatment of Inoperable Cancer.” It noted that “200 years ago it was observed that a certain number of malignant growths disappeared after an attack of erysipelas [a type of …

The Effects of Nutritional Yeast for Cancer  Read More »

‘Luckiest Man Alive’: Why 9/11 First Responders’ Outlooks May Improve Even as Physical Health Fails

Ray Pfeifer and Luis Alvarez’s names are on the federal 9/11 legislation that establishes benefits for first responders. Both men fought to make Congress pass it while they were dying of cancer — and they had another thing in common. In spite of it all, they were content. “I am the luckiest man alive,” Pfeifer, …

‘Luckiest Man Alive’: Why 9/11 First Responders’ Outlooks May Improve Even as Physical Health Fails Read More »

Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative for Precision Cancer Treatment

What You Should Know: – Cedars-Sinai Cancer and Tempus, a provider of artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each individual’s disease. …

Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative for Precision Cancer Treatment Read More »

Roche bets $300M on Adaptimmune tech for off-the-shelf cell therapies for cancer

Roche is partnering with Adaptimmune Therapeutics to develop allogeneic cell therapies based on Adaptimmune’s technology. In addition to these “off-the-shelf” products, the partners will also develop a personalized allogeneic cell therapy designed specifically for a patient’s cancer.

Startup Modulus embraces AI to design better NK cell therapies for cancer

Modulus Therapeutics recently emerged from stealth with technology from various disciplines and seed funding that the startup is using to develop better cell therapies. Natural killer cells directed against breast cancer is Modulus’s initial focus, but the startup says its approach can apply to multiple types of immune cells and multiple types of cancer.

Targeting COVID-19 and cancer with immunotherapy advancements

Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Over the last 30 years, we have seen dramatic improvements in patient outcomes due to the emergence of biologics – particularly monoclonal antibodies – as therapies for a wide variety of diseases and infections. Monoclonal antibodies (mABs) are highly specific therapies associated with …

Targeting COVID-19 and cancer with immunotherapy advancements Read More »

Takeda’s Pevonedistat Fails to Meet Primary Endpoints in P-III PANTHER Trial as 1L Treatment for Patients with Rare Bone Marrow Cancer

Shots: The P-III PANTHER trial evaluates pevonedistat + azacitidine vs azacitidine alone in patients with higher-risk MDS, CMML and AML The study did not achieve its pre-defined 1EPs of EFS, the safety profile was consistent with previously reported data of the combination regimen Pevonedistat is an NAE inhibitor that leads to cancer cell death by …

Takeda’s Pevonedistat Fails to Meet Primary Endpoints in P-III PANTHER Trial as 1L Treatment for Patients with Rare Bone Marrow Cancer Read More »

How pharma can help the post-COVID recovery of European cancer care

The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians implemented during the acute phase of the pandemic, with a focus on the way in which treatment strategies were altered. The publication, which has been supported by Accord Healthcare, also provides a series of …

How pharma can help the post-COVID recovery of European cancer care Read More »

Asher Bio’s encouraging early data against rival cancer drug sparks $108M financing

Five months after raising $55 million to back a new technology and a promising lead cancer immunotherapy, Asher Biotherapeutics has reeled in $108 million more. CEO Craig Gibbs said investors were enticed by encouraging new data suggesting Asher Bio’s lead program is superior to a competitor’s.

Recognizing National Immunization Awareness Month

Vaccines have played a critical role in reducing the spread of, and in some cases, eliminating the threat of many devastating infectious diseases. They are often cited as second only to clean drinking water in leading to some of the most impactful public health advances in history, including the eradication of smallpox globally and measles, …

Recognizing National Immunization Awareness Month Read More »

MedStar Health, MercyOne, Moffitt Cancer Center, Others Double Down on Digital Transformation

What You Should Know: – AVIA, the nation’s leading healthcare innovation network, today announced that the following six new health system Members joined the AVIA Network to accelerate their digital strategies and advance digital capabilities: Lee Health, LifeBridge Health, MedStar Health, MercyOne,   Moffitt Cancer Center, Multicare. Additionally, AVIA had a record of 100% plus renewal rate from existing Members. – Executive leaders from health systems are prioritizing digital and understand the critical role it plays to …

MedStar Health, MercyOne, Moffitt Cancer Center, Others Double Down on Digital Transformation Read More »

Ontada, Merck Partner to Facilitate Real World Evidence Studies for Cancer Care

What You Should Know: – Ontada, McKesson’s oncology and insights business, announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation. This agreement enables the two healthcare leaders to harness the power of real-world evidence (RWE) towards the common …

Ontada, Merck Partner to Facilitate Real World Evidence Studies for Cancer Care Read More »

A biotech startup’s hunt for elusive disease targets scores $60M for drug R&D

Atavistik Bio is one of several companies discovering and developing drugs that work by allostery, binding to less obvious sites of a target protein. Acting CEO John Josey said the startup aims to stand apart with its focus on understanding metabolic interactions, a path less trodden by others in allosteric drug discovery.

Jasper Health Integrates BioIntelliSense’s RPM and COVID-19 Screening Solution for Members

What You Should Know:  – Today, BioIntelliSense announced it has formed a strategic collaboration with Jasper Health, an emerging leader of digital engagement for people diagnosed with cancer. – As part of the strategic collaboration, Jasper Health will integrate the BioIntelliSense FDA-cleared BioSticker and medical grade BioButton® wearable devices as part of its remote member …

Jasper Health Integrates BioIntelliSense’s RPM and COVID-19 Screening Solution for Members Read More »

Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care

What You Should Know:  – Foundation Medicine (FMI) announced today a partnership to integrate its comprehensive genomic testing services into Epic’s electronic medical record (EMR) platform, making it easier for oncologists to order comprehensive genomic tests (CGP), review results, continually access clinical and genomic information and share among their care teams in order to develop …

Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care Read More »

ADC Therapeutics strikes a $325M royalty deal to fuel its cancer drug strategy

The royalty agreement with HealthCare Royalty Partners will support ADC Therapeutics’ plans to commercialize its newly approved cancer drug and develop the next one in its pipeline. The biotech’s drug Zynlonta is the first of its type approved by the FDA as a treatment for diffuse large cell B-cell lymphoma

Soy Phytoestrogens for Menopausal Symptoms

Does soy food consumption explain why Japanese women appear to be so protected from hot flash symptoms? When women hit menopause and their ovaries shut down, the estrogen level in their body drops 95 percent. This is good news for the endometrium, the lining of the uterus. Otherwise, the constant estrogen signaling could eventually result in endometrial cancer. In fact, …

Soy Phytoestrogens for Menopausal Symptoms Read More »

AstraZeneca’s Ultomiris; HebaBiz’s Siroquine; Pfizer’s XELJANZ; Bristol Myers Squibb’s Opdivo; and Masimo’s PVi

AstraZeneca’s Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral Sclerosis AstraZeneca’s 39 billion USD complete acquisition of Alexion took over just a few months back. Unpleasant news strike hard for their first deal in the rare neurodegenerative disease domain. Alexion focuses on finding medications for …

AstraZeneca’s Ultomiris; HebaBiz’s Siroquine; Pfizer’s XELJANZ; Bristol Myers Squibb’s Opdivo; and Masimo’s PVi Read More »

Pfizer makes big move in blood cancers with $2.3B Trillium acquisition

Though Gilead Sciences leads the group of companies developing immunotherapies that target the cancer protein CD47, Pfizer contends that molecules it is getting through the Trillium Therapeutics acquisition have safety and efficacy advantages that could make them the best in this emerging drug class.

Illumina’s Grail buyout beats deadline, but legal and regulatory hurdles remain

In closing its Grail acquisition before U.S. and European regulators sign off, Illumina is taking a chance the deal will pass regulatory muster. It’s a potentially pricey gambit, as Illumina could face fines for its early action and there are no assurances that regulators will agree that the deal is not anticompetitive.

FDA decision for GSK drug opens door to treatment of more cancer patients

GlaxoSmithKline drug Jemperli is now FDA approved for treating solid tumors throughout the body as long as they have a particular genetic signature. Expanding the drug’s approval means the drug can treat more patients who have more types of cancer, and it also gives GSK a way to grow revenue in its thin oncology portfolio.

HiberCell’s Genuity buyout brings $100M, plus alliances with Ionis and AbbVie

Startup HiberCell has acquired Genuity Science, a marriage that brings together two companies that apply AI and machine learning to drug research. HiberCell says Genuity will help the company identify and validate new pathways in how cancer starts and progresses.

Sesen Bio says rejected bladder cancer drug may need new clinical trial

For much of this summer, Sesen Bio said all of the FDA’s communications pointed toward regulatory approval for the biotech’s bladder cancer drug. Though Sesen characterized the regulator’s rejection of the fusion protein as surprising, CEO Tom Cannell also revealed an earlier sign that another clinical trial may be necessary.

Merck drug acquired in $1B deal approved to treat tumors sparked by rare disease

FDA approval of the Merck drug, belzutifan, covers treatment of tumors caused by von Hippel-Lindau disease, an inherited disorder associated with several types of cancer. Merck added the small molecule to its pipeline two years ago as part of a $1.2 billion acquisition.

Noncoding RNA Therapies

I was mentioning the number of unusual therapeutic modes that are being explored these days, and one of those is (broadly) RNA-based approaches. The ones that directly feed into coding for proteins get a lot of attention (the mRNA vaccines, for example), and everything that’s currently approved is some sort of antisense or siRNA species. …

Noncoding RNA Therapies Read More »

Second FDA clinical hold for Aprea cancer drug cites safety data in another study

For the second time in a week, the FDA placed a clinical hold on an Aprea Therapeutics cancer drug. The biotech said the agency cited safety and efficacy data from a prior failed clinical trial that tested the small molecule in a different form of cancer.

The Dangers of Talcum Powder

What role does diet and baby powder play in the development of fibroids and ovarian cancer?  If you randomly select a group of women and ultrasound their uterus, most of them have fibroid tumors by age 50—and by most, I mean more than 80 percent of black women and nearly 70 percent of white women. As you can see at 0:23 in my video Talcum …

The Dangers of Talcum Powder Read More »

Breast cancer drug approved for NHS after maker agrees discount

Reversal of earlier rejection by Nice of abemaciclib – known as Verzenios – is welcomed by campaigners A breast cancer drug that was rejected for routine NHS use in England earlier this year has now been recommended by health officials after a discount was agreed with the manufacturer. The decision has been described as “fantastic …

Breast cancer drug approved for NHS after maker agrees discount Read More »

Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer

Shots: Appia Bio to receive $875M as an up front, equity investment, and milestone along with royalties. Kite will be responsible for the development, manufacturing, and commercialization of the product identified through the collaboration The collaboration will utilize Kite’s chimeric Ag receptors and Appia Bio’s allogeneic cell technology platform to develop off-the-shelf cell therapies Appia …

Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer Read More »

A New Pathway To Kill Resistant Breast Cancer

As all the recent news about protein folding should make clear, there are a lot of ways for any given protein sequence to come together into a three-dimensional structure. For that phrase “a lot”, substitute “a larger number than the human mind can possibly comprehend”, and you’ll be about right. Biologically, many proteins already display …

A New Pathway To Kill Resistant Breast Cancer Read More »

Dr. Greger’s Daily Dozen Healthiest of Healthy Foods 

In my book How Not to Die, I center my recommendations around a Daily Dozen checklist of everything I try to fit into my daily routine.  In my book How Not to Die, I suggest we try to center our diets around whole plant foods. Some plants are healthier than others, though. Apparently, you can live for extended periods eating practically nothing but white potatoes, for example, …

Dr. Greger’s Daily Dozen Healthiest of Healthy Foods  Read More »

Amgen adds antibody assets and R&D tech with $900M Teneobio acquisition

Amgen is paying $900 million up front to acquire Teneobio, a biotech with technology for discovering and developing antibody drugs. Though Amgen already has its own antibody platform, the company says Teneobio’s technology and drug assets will complement its own.

Is medical cannabis really a magic bullet?

Research increasingly suggests that extracts from the plant are effective in treating pain, anxiety, epilepsy and more, but experts still preach caution around recreational use In 2017, Mikael Sodergren, a liver and pancreatic cancer surgeon at Imperial College healthcare NHS trust, was finding himself becoming increasingly interested in the potential role of medical cannabis in …

Is medical cannabis really a magic bullet? Read More »

Frontier Medicines raises $88M for R&D, including potential rival to Amgen cancer drug

Cancer drug developer Frontier Medicines already has a research partnership with AbbVie. Now the preclinical-stage biotech has raised $88.5 million for its own pipeline, including a drug that could offer advantages over a recently approved Amgen cancer therapy.

Wugen unveils $172M to take natural killer cell therapies to solid tumors

Wugen, a biotech developing “off-the-shelf” natural killer and CAR T cell therapies, has raised $172 million in Series B financing. The company’s lead program has already reached human testing and the new capital will be used to continue that research and advance other pipeline programs to the clinic.

A Fifty-Year-Old Cancer Drug Doesn’t Do What You Think

5-fluorouracil (5-FU) has been around a long time now (over fifty years), and it’s a standard oncology drug (particularly in colorectal treatment regimes). But try going around and asking people how it works. If you’re talking to a clinician and want to seem up on the lingo, just say “What’s 5-FU’s MOA?” (mechanism of action). …

A Fifty-Year-Old Cancer Drug Doesn’t Do What You Think Read More »

Elekta to work with academics on AI-directed radiotherapy

Radiotherapy specialist Elekta has joined forces with two academic groups in the Netherlands to explore the use of artificial intelligence (AI) to deliver more effective personalised therapy to patients.  The Swedish company will collaborate with scientists at the Netherlands Cancer Institute and University of Amsterdam (UvA) on a project that aims to use AI to …

Elekta to work with academics on AI-directed radiotherapy Read More »

What HCPs think about health equity in cancer care

After more than a year of COVID-19 dominating health conversations, HCPs have been engaging in dialogue about continually evident disparities that many are facing in healthcare. CREATION.co’s Mary Kangley explores what HCPs think about health equity in cancer care. The topic rose to significance in the American Society of Clinical Oncology (ASCO) whereby they updated …

What HCPs think about health equity in cancer care Read More »

Oil Pulling for Cancer? 

What evidence exists to suggest oil pulling can effectively treat serious diseases, such as paralysis, meningitis, cancer, and AIDS?  I’ve produced videos on how coconut oil is safe to put on your hair or put on your skin, but you certainly don’t want to eat it. In fact, you may not even want to be in the same kitchen when coconut oil is being heated. I don’t know where people got the idea …

Oil Pulling for Cancer?  Read More »

Biotech startup using AI to take guesswork out of cancer drug selection raises $70M

Xilis is developing technology that creates a living model of a patient’s tumor, then applies artificial intelligence to determine the best drug or drug combinations to treat the cancer. Clinical trials are planned to test this precision medicine approach and the biotech startup has raised $70 million to fund its research.

Health Innovators: Eliot Forster, F-Star

In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Eliot Forster, CEO of F-Star – a clinical-stage, NASDAQ-listed biopharmaceutical company focused on transforming the lives of patients with cancer.     About the author Dr Paul Tunnah is chief content officer and UK managing director for Healthware Group, a next-generation integrated consulting group that …

Health Innovators: Eliot Forster, F-Star Read More »

What mRNA is Good For, And What It Maybe Isn’t

The huge success of the mRNA vaccination platform during the pandemic has set a lot of people to thinking about what comes next. Moderna and BioNTech, of course, have been thinking this way for quite some time. But Sanofi now says that they’ll be investing large amounts into the technology, and this previously hadn’t been …

What mRNA is Good For, And What It Maybe Isn’t Read More »

Novobiocin Returns? But Not as an Antibiotic.

Here’s some interesting work from Dana-Farber (earlier BioRxiv version here) that may turn into a rare example of repurposing an old drug, if it works out. The team was studying an enzyme called DNA polymerase theta (also known by its corresponding gene name, POLQ), which is one of the lesser-known members of that functional family. …

Novobiocin Returns? But Not as an Antibiotic. Read More »

Lyell, Verve IPOs raise a combined $692M as both biotechs steer toward clinical trials

Lyell Immunopharma and Verve Therapeutics are still preclinical, but they’re bring novel genetic approaches to the treatment of cancer and cardiovascular disease. Now the two companies can claim two of the biggest biotech IPOs of 2021 so far.

Goal Attainment Scaling

What outcomes should be used to measure if a medicine is a “good” medicine? Improved survival? Improved ability to function? Few side effects? Ability to get back to work? Living to attend your daughter’s wedding? All of the above? Oftentimes, health economists measure value of a treatment for the average person. Preferences for efficacy, safety, …

Goal Attainment Scaling Read More »

GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer

Shots: iTeos to receive $625M up front & is eligible to receive up to ~$1.45B in milestone upon achievement of certain milestones & royalties on ex-US sales. Both companies will share global development costs of EOS-448 and co-commercialize & share profits in the US GSK to receive an exclusive license for commercialization (Ex-US) & access …

GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer Read More »

ASCO 2021 recap: Lynparza’s lift, Grail goes on, LAG validation & more

The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.

INVEST Precision Medicine conference kicks off today. Register now to be part of the conversation.

Register for the INVEST Precision Medicine conference, which kicks off today. Over the next three days industry experts will talk about precision medicine developments across pediatrics, bioinformatics, startups and more.

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. Home to over 60% of the world’s population, Asia Pacific (APAC) is not a region the biopharma industry can afford to ignore. Dr Jay Mei, founder and …

Country focus: China & APAC’s growing medical needs bring opportunities and challenges Read More »

Merus eyes tumor-agnostic path for cancer drug addressing rare genetic target

Cancer drug developer Merus has encouraging early results indicating its drug can address several different types of tumors characterized by NRG1, a rare gene fusion. The company believes the data could support a regulatory filing for the bispecific antibody drug.

Auris Medical pivots from hearing loss drugs, joins red hot RNA therapies field

Auris Medical has acquired Trasir Therapeutics, a startup developing technology that expands the delivery of RNA medicines to tissues beyond the liver. Going forward, Auris will sell or spin off its programs in hearing disorders and allergies and focus exclusively on RNA therapies.

Changing focus to cachexia may be key to improved cancer outcomes

Cachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. Physician and researcher Dr. Daniel L Marks discusses the historial challenges to developing a therapeutic for this condition and what may finally be on the horizon.  Until recently, cancer research and resulting therapeutic approaches have focused on one …

Changing focus to cachexia may be key to improved cancer outcomes Read More »

MorphoSys to buy Constellation Pharma in a $1.7B bet on epigenetic cancer drugs

MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the acquisition with cash from a separate $2 billion deal with drug royalty acquirer Royalty Pharma.

AI Disease Modeling Supports Precision Medicine for Cancer

Precision medicine has offered a lot of hope for the treatment of cancer, as it makes it possible to tackle the multi-faceted disease with a more personalized, patient-specific approach. Meanwhile, researchers are also becoming increasingly interested in applications for artificial intelligence in the development of drugs and therapies. Could AI and precision medicine work together …

AI Disease Modeling Supports Precision Medicine for Cancer Read More »

Engine Biosciences revs up $43M for AI tech that yields targeted cancer therapies

Engine Biosciences closed a $43 million Series A financing that the startup will apply to its artificial intelligence-based technology for drug discovery. The company analyzes genetic interactions, “deciphering biology” to find new cancer drugs.

Tomato Sauce Put to the Test for Prostate Cancer

What happened when cancer patients were given three quarters of a cup of canned tomato sauce every day for three weeks? “Occasionally…positive things happen in the field of cancer prevention science to popular, good-tasting foods.” Cruciferous vegetables like broccoli are wonderful, but they may be “a hard food for the public to swallow.” By contrast, …

Tomato Sauce Put to the Test for Prostate Cancer Read More »

Lycopene Supplements Put to the Test

High doses of lycopene—the red pigment in tomatoes—were put to the test to see if it could prevent precancerous prostate lesions from turning into full-blown cancer. Back in 1980s, the Adventist Health Study found “strong protective relationships” against prostate cancer with increasing consumption of legumes, citrus, dried fruit, nuts, and tomatoes. In the 1990s, a …

Lycopene Supplements Put to the Test Read More »

LAG-3 drugs take centre stage at ASCO, showing potential as next-gen immunotherapies

LAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this year’s ASCO conference after trial results showed their potential as next-generation cancer immunotherapies. Bristol-Myers Squibb made a splash ahead of the virtual conference early next month, with results showing a single infusion of its LAG-3 blocker relatlimab …

LAG-3 drugs take centre stage at ASCO, showing potential as next-gen immunotherapies Read More »

Numab raises $110m to develop cancer bispecific antibodies

Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. Proceeds will support acceleration and expansion of the clinical development of Numab’s lead drug NM21-1480 into several cancer indications. It …

Numab raises $110m to develop cancer bispecific antibodies Read More »

FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option

The FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected to compete on price with rivals such as Merck & Co’s Keytruda. The companies filed for approval for the PD-1 inhibitor in untreated nonsquamous non-small lung cancer in combination with pemetrexed and platinum chemotherapy. It’s the first …

FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option Read More »

BMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drug

Bristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to a cancer antibody still in the labs of US biotech Agenus, which blocks the TIGIT receptor that is emerging as an immunotherapy target. Roche is one of the leaders in research in to TIGIT – short for …

BMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drug Read More »

Amla (dried Indian gooseberry) vs. Lipitor for Lowering Cholesterol

Extracts of amla (Indian gooseberry) were pitted head-to-head against cholesterol-lowering statin drugs and the blood thinners aspirin and Plavix. Indian gooseberries, otherwise known as amla, have been touted as everything from a cancer fighter to a hair tonic to a refrigerant. (A refrigerant? Like Freon?) Amla’s even been labeled a snake venom detoxifier—but based on …

Amla (dried Indian gooseberry) vs. Lipitor for Lowering Cholesterol Read More »

‘Kicking You When You’re Down’: Many Cancer Patients Pay Dearly for Parking

For cancer patients, the road from diagnosis to survivorship feels like a never-ending parade of medical appointments: surgeries, bloodwork, chemotherapy, radiation treatments, scans. The routine is time-consuming and costly. So, when hospitals charge patients double-digit parking fees, patients often leave the garage demoralized. This story also ran on NBC News. It can be republished for …

‘Kicking You When You’re Down’: Many Cancer Patients Pay Dearly for Parking Read More »

The Most Antioxidant-Packed Whole Food

Are the apparently amazing benefits of amla—dried Indian gooseberries—too good to be true? In reference to amla, also known as the Indian gooseberry, it’s been said that “medicinal plants are nature’s gift to human beings to promote a disease free healthy life.” The fruit has also been described as “the Ayurvedic wonder.” You hear a …

The Most Antioxidant-Packed Whole Food Read More »

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecan

AstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – and although it’s from a small patient group results look impressive. To recap, AZ shelled out $1bn for rights to datopotamab last year, an antibody-drug conjugate (ADC) consisting of an antibody that targets tumours and a lethal …

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecan Read More »

Redesign Health Spinout Jasper Health Launches AI-Driven Cancer Care Platform

What You Should Know: – Jasper Health launched today as the first end-to-end care experience that navigates, connects, and provides actionable insights throughout the cancer journey for individuals with cancer, their caregivers, and providers. – Jasper combines an easy-to-navigate user interface with leading oncology support to help guide Jasper Members and caregivers through the myriad …

Redesign Health Spinout Jasper Health Launches AI-Driven Cancer Care Platform Read More »

Mayo Clinic strikes remote patient monitoring partnership with NXgenPort

Mayo Clinic is ramping up activity in the remote patient monitoring arena. Its latest move is a collaboration with biomedical technology company NXgenPort, which will focus on an implantable catheter that can remotely monitor cancer patients for complications as they undergo treatment.

CRISPR Therapeutics begins natural killer cell cancer tie-up with Nkarta

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. This latest agreement follows a major deal with Vertex last month, where CRISPR announced it is to receive $900m in a reworked collaboration, to develop a gene editing therapy for sickle cell disease …

CRISPR Therapeutics begins natural killer cell cancer tie-up with Nkarta Read More »

Are Avocados Associated with Greater Risk or Reduced Risk of Cancer?

Avocado consumption can improve artery function, but what effect might guacamole have on cancer risk? In my last video about avocados, The Effects of Avocados and Red Wine on Meal-Induced Inflammation, I described their anti-inflammatory effects and cholesterol- and triglyceride-lowering effects, but what about the Are Avocados Good for You? video I did years ago …

Are Avocados Associated with Greater Risk or Reduced Risk of Cancer? Read More »

Cancer Centers: Here’s How We Can Restart Clinical Trials Today

Marie E. Lamont, President and COO of Inteliquet Biopharmaceutical companies developing cancer treatments need to restart the clinical trials shut down or delayed during the early stages of the coronavirus pandemic. Some are holding back, however, due to a lack of confidence that sufficient eligible patients can be recruited and enrolled in the trials. Recruiting …

Cancer Centers: Here’s How We Can Restart Clinical Trials Today Read More »

Roche’s Tecentriq gets fourth European lung cancer indication

Roche’s cancer immunotherapy Tecentriq has been granted a new use by European regulators, for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC). Tecentriq (atezolizumab) has now been used in Europe for adults with metastatic NSCLC whose tumours have high PD-L1 expression. The tumours must also have no epidermal growth factor …

Roche’s Tecentriq gets fourth European lung cancer indication Read More »

Natural Dietary Treatments for Fibroids

The same diet that helps regulate hormones in women may also reduce exposure to endocrine-disrupting pollutants. Fibroids are the most common benign tumors in women. They can grow to a foot in diameter and affect the majority of women before they hit menopause. Although fibroids tend to be asymptomatic, when symptoms do occur, they tend …

Natural Dietary Treatments for Fibroids Read More »

Two new biotechs unveil $112M combined for antibody drug conjugates for cancer

The list of FDA-approved antibody drug conjugates (ADC) is growing, and two more biotech startups have emerged from stealth with new cash and new approaches to this type of cancer drug. Adcendo and Adcentrx raised a combined $112 from their Series A financings.

Two Steps to Activation

Engineering immune system cells to do what we’d like them to do is one of the big areas of medical research these days, and this new paper could be a real advance in the area. A team out of UCSF with several collaborators reports on a new way around one of the big problems in …

Two Steps to Activation Read More »

Tecentriq can stay as therapy for triple-negative breast cancer, FDA experts say

Roche’s Tecentriq can stay on the US market as a therapy for triple negative breast cancer, advisers to the FDA have said as part of a review of several quickly-approved cancer drugs. Tecentriq was the first drug to be discussed in the review by the FDA’s Oncologic Drugs Advisory Committee (ODAC) of cancer drugs that …

Tecentriq can stay as therapy for triple-negative breast cancer, FDA experts say Read More »

FDA approves under-pressure GSK’s Jemperli for endometrial cancer

The FDA has approved GlaxoSmithKline’s Jemperli (dostarlimab) immunotherapy, a drug acquired through its $5.1 billion acquisition of Tesaro, for certain patients with endometrial cancer.  With Jemperli, a PD-1 class drug, GSK is a latecomer to the immunotherapy party with a host of other competitors already on the market in various cancers. Merck & Co’s Keytruda …

FDA approves under-pressure GSK’s Jemperli for endometrial cancer Read More »

Centessa plans $100m IPO to fund R&D and potential acquisitions

Centessa has announced plans for a $100m US IPO just weeks after the company launched with $250m in private backing and an R&D powerhouse driven by the merger of 10 biotechs. In a filing with the Securities and Exchange Commission, Centessa said it plans to use proceeds to fund the development of the 16 drugs …

Centessa plans $100m IPO to fund R&D and potential acquisitions Read More »

Regulatory progress for two biotechs stalls as FDA requests more information

The FDA placed a clinical hold on a KalVista Pharmaceuticals drug being readied for mid-stage studies in a rare, inherited disorder. Meanwhile, the FDA has some questions about the historical data Y-mAbs used as the control in a clinical trial for its antibody cancer drug.

NorthShore, Sema4 set up genomics program to advance personalized treatment

The Illinois-based health system is teaming up with the analytics company to launch a genomics program, which will focus on predicting the risk of illness and outcomes among patients. It will also provide free genetic testing to low-income patients in an effort to increase access to genomic care.

Should You Get an Annual Physical Exam?

What are the risks and benefits of getting a comprehensive annual physical exam and routine blood testing? The model of getting an annual physical exam dates back nearly a century in American medicine, but recently, many health authorities “have all agreed that routine annual checkups for healthy adults should be abandoned”—yet, the majority of the …

Should You Get an Annual Physical Exam? Read More »

J&J decides against Erleada+Zytiga combination prostate cancer filing

Johnson & Johnson won’t be filing a prostate cancer therapy combining its Erleada and Zytiga drugs with regulators, after a phase 3 trial showed it didn’t improve survival compared with Zytiga alone. Zytiga is the older of the two drugs and was used in the active control arm of the ACIS study, which tested the …

J&J decides against Erleada+Zytiga combination prostate cancer filing Read More »

Non-Small Cell Lung Cancer Drug Development Summit

The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. This is a strategic conference designed to bring drug development teams together to address critical challenges surrounding therapeutic potency, tumor resistance and relapse and expanding the clinical utility of targeted and immuno-therapies, either in combination or …

Non-Small Cell Lung Cancer Drug Development Summit Read More »

Activist investor Elliott builds stake in GSK after fresh trial upset

Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn around the company’s fortunes. The news follows another trial disappointment this week, where GSK’s feladilimab, combined with Merck & Co’s Keytruda (pembrolizumab), came up short in a …

Activist investor Elliott builds stake in GSK after fresh trial upset Read More »

C2i Genomics Raises $100M for Whole-Genome Cancer Treatment Intelligence Platform

– Cancer intelligence company, C2i Genomics announced it has raised $100M in financing from Casdin Capital, NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others. – Funds will be used to accelerate clinical development and commercialization of the company’s C2-Intelligence Platform, a cancer diagnostics service, that uses AI pattern recognition and whole-genome …

C2i Genomics Raises $100M for Whole-Genome Cancer Treatment Intelligence Platform Read More »

Should You Get an Annual Health Check-Up?

What are the risks and benefits of getting an annual check-up from your doctor? Physicians and patients have come to expect the annual check-up as a routine part of care. “However, considerable research has not demonstrated a substantial benefit,” so a “revolt is brewing against the tradition of periodic” check-ups. “Even the Society for General …

Should You Get an Annual Health Check-Up? Read More »

Boehringer and MD Anderson extend KRAS cancer collaboration

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations.  The collaboration was launched in 2019 and in its next phase will explore new molecules from Boehringer’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios, with a …

Boehringer and MD Anderson extend KRAS cancer collaboration Read More »

Gilead’s Trodelvy approved in metastatic urothelial cancer

Gilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer.  Trodelvy (sacituzumab govitecan) has been approved for locally advanced or metastatic urothelial cancer, following a platinum-containing chemotherapy and PD-1/PD-L1 inhibitor immunotherapy. The US pharma hopes that the drug will be used in those patients who have not …

Gilead’s Trodelvy approved in metastatic urothelial cancer Read More »

AZ aims at Pfizer, GSK with potential new PARP cancer drug

AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer.  The drug has gone on to become a huge success, generating sales of nearly $1.8 billion in 2020 alone as part of a partnership with Merck & Co after expanded use in …

AZ aims at Pfizer, GSK with potential new PARP cancer drug Read More »

Biotech startup Repertoire adds $189M to expand array of immune medicines

With two cancer programs already making progress, Repertoire Immune Medicines will use the Series B financing to expand its immune synapse research to autoimmune disorders and infectious disease. CEO John Cox said his startup’s approach could advance immune medicines beyond the scope of currently available therapies.

Do Cell Phones Cause Brain Tumors?

What does the world’s leading authority on carcinogens have to say about mobile phones? Do cell phones cause cancer? That’s a question billions of people would like to have answered and one I address in my video Cell Phone Brain Tumor Risk?. That’s why we have the World Health Organization’s International Agency for Research on …

Do Cell Phones Cause Brain Tumors? Read More »

Philips, Ibex Medical Analytics Partner on AI-Powered Digital Pathology Adoption

What You Should Know: – Philips and Ibex Medical Analytics announced a strategic partnership to globally commercialize clinically proven, AI-powered digital pathology solutions. The collaboration further cements Philips’ commitment to integrated diagnostics providing a clear path to precision diagnosis. – The trend towards centralized pathology labs, the global shortage of trained pathologists, and increasing demands on histopathology …

Philips, Ibex Medical Analytics Partner on AI-Powered Digital Pathology Adoption Read More »

Can Cell Phone Radiation Damage Your DNA?

Do mobile phones cause brain tumors? Whenever a trillion-dollar industry is involved—whether it’s Big Food, Big Tobacco, Big Pharma, or Big Telecom—there’s so much money that the science can get manipulated. When it comes to the potential human health effects of cell phone use, certainly, you might end up with a crick in your neck …

Can Cell Phone Radiation Damage Your DNA? Read More »

Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching

What You Should Know: – Today, Deep Lens and Cardinal Health announced a strategic collaboration that will integrate Deep Lens’ AI-based clinical trial matching solution, VIPER, into community-based oncology practices throughout the Cardinal network. VIPER will be a part of Cardinal Health’s new Navista advanced suite of technology solutions designed to help oncologists improve outcomes, …

Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching Read More »

Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases

That is the title of a paper I just published at Value in Health with Suepattra G. May, Lauren M. Zhao, Katalin Bognar, Yong Yuan, John R. Penrod, and John A. Romley. The subtitle is A Stated Preference Survey of Adults Diagnosed With and Without Lung Cancer. The full abstract is below: Objectives: To compare …

Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases Read More »

Is Cocamidopropyl Betaine in Toothpaste Better Than Sodium Lauryl Sulfate?

For those with recurrent canker sores, is it better to use a toothpaste with SLS, CAPB, or no foaming agents at all? Sodium lauryl sulfate (SLS) had already been used as a foaming agent in toothpastes for more than a half-century by the time a study was published showing tissue damage in most of those …

Is Cocamidopropyl Betaine in Toothpaste Better Than Sodium Lauryl Sulfate? Read More »

mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer

Shots: The EC has approved MB02 biosimilar to Avastin (Bevacizumab) in the EU for the treatment of carcinoma of the colon or rectum, BC, NSCLC, RCC, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix Mabxience’s MB02 to be marketed as Alymsys and Oyavas both show comparable quality, safety & efficacy …

mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer Read More »

Is Sodium Lauryl Sulfate (SLS) in Toothpaste Safe?

Just because the sodium lauryl sulfate in toothpaste doesn’t cause cancer doesn’t mean it can’t cause problems. Sodium lauryl sulfate (SLS) is a common detergent used in toothpaste. It was featured in a famous Internet hoax nearly 20 years ago. Colgate toothpaste contains SLS, which was supposedly proven to cause cancer, but at least buying …

Is Sodium Lauryl Sulfate (SLS) in Toothpaste Safe? Read More »

COVID Exposed The Dire Need for Real-Time Healthcare Data Sharing

Birju Shah, Head of Product for Uber Health & Communities Nick Jordan, Founder and CEO, Narrative In a world where technology and Big Data can provide us with instantaneous access to our banking transactions, and our financial information and credit reports can be retrieved with a few keystrokes when applying for a mortgage — trying to …

COVID Exposed The Dire Need for Real-Time Healthcare Data Sharing Read More »

Helpful Foods to Support People with Autism

The sulforaphane found in five cents’ worth of broccoli sprouts has been shown to benefit autism in a way no drug ever has in a randomized, double-blind, placebo-controlled study. You may remember my series of videos, which includes Prevent Cancer from Going on TOR, about target of rapamycin (TOR), the engine-of-aging enzyme. Kids with autism …

Helpful Foods to Support People with Autism Read More »

Getting a Prescription to Die Remains Tricky Even as Aid-in-Dying Bills Gain Momentum

Linda Heim knew her dad didn’t plan to wait for the cancer to kill him. For decades, he’d lived in Montana, which they’d thought was one of the few places where terminally ill people could get a prescription to end their life. This story also ran on Time. It can be republished for free. After …

Getting a Prescription to Die Remains Tricky Even as Aid-in-Dying Bills Gain Momentum Read More »

Omega Healthcare Acquires himagine Solutions to Expand Global Delivery Model

What You Should Know: – Omega Healthcare, a provider of outsourced revenue cycle management and other healthcare support services, today announced the acquisition of himagine Solutions, a St. Louis based provider of medical coding and registry services. The transaction expands the service capabilities and geographical footprint of both companies, enhancing the ability to service clients globally. – Through this acquisition Omega Healthcare will …

Omega Healthcare Acquires himagine Solutions to Expand Global Delivery Model Read More »

To Advance Health Equity, Put Real-World Cancer Data to Work

Dr. Miller, Medical Director of CancerLinQ LLC Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons — like institutional racism and poverty — are a reflection of our broader society. Other inequities may go unrecognized but are no less damaging. People with underlying health conditions, for example, …

To Advance Health Equity, Put Real-World Cancer Data to Work Read More »

COSMIC database matches drugs to cancer mutations

The world’s largest database of cancer mutations can now be used to link mutations with drug treatments in what promises to be a step forward in precision oncology.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database, operated by the Wellcome Sanger Institute, grew out of the work of the Cancer Genome Project and has …

COSMIC database matches drugs to cancer mutations Read More »

Cancer services should be rebuilt after COVID disruption, experts say

There is a pressing need for a joined-up cancer strategy to reverse the impact of the COVID-19 pandemic, according to a new report from the UK’s pharma industry. The Association of the British Pharmaceutical Industry (ABPI) report said that the UK must be more ambitious with its cancer strategy if it is to compete with …

Cancer services should be rebuilt after COVID disruption, experts say Read More »

NeoGenomics Acquires Precision Oncology Platform Trapelo Health for $65M

What You Should Know: – NeoGenomics, Inc., a provider of cancer-focused genetic testing services and global oncology contract research services announced it has reached an agreement to acquire precision oncology platform Trapelo Health for $65M. The agreement purchase price of $65 million, consists of $35 million in cash on hand and $30 million in NeoGenomics …

NeoGenomics Acquires Precision Oncology Platform Trapelo Health for $65M Read More »

Instil Bio’s upsized IPO raises $320M for clinical tests of TIL cancer cell therapy

Instil Bio, one of several companies developing tumor-infiltrating lymphocytes, will use its IPO cash to advance its clinical testing plans. Meanwhile, Finch Therapeutics and Gain Therapeutics also priced IPOs to fund clinical trials.

How do you get all the data quality benefits of eCOA in less time and at lower cost?

Upcoming oncology trial? Which oncology eCOA Package offers the best ability to capture reliable endpoint evidence to increase speed, reduce cost, and ensure consistency across sites and geographies in less time? Find out. Consider these data points: 334 studies 158,000+ patients 67 countries 44,000+ sites 116 languages 30+ indications 33% Faster Design with an Average …

How do you get all the data quality benefits of eCOA in less time and at lower cost? Read More »

Benefits of Turmeric for Arsenic Exposure

What happened when turmeric curcumin was put to the test to see if it could reverse DNA damage caused by arsenic exposure? Arsenic is a carcinogenic heavy metal, and the major mechanism of arsenic-related damage appears to be oxidative stress. It’s the arsenic-induced accumulation of free radicals that can kill off cells and damage our …

Benefits of Turmeric for Arsenic Exposure Read More »

Achieving Financial Sustainability: A Connected Community of Care’s #1 Goal

Dr. Keith Kosel, Vice President at Parkland Center for Clinical Innovation (PCCI) “Show me the money!” No one old enough to have seen the 1996 movie, Jerry Maguire, will ever forget that memorable phrase. That simple but powerful phrase could apply to every person who punches a clock for a living and just about every …

Achieving Financial Sustainability: A Connected Community of Care’s #1 Goal Read More »

Aveo Oncology’s kidney cancer drug gets FDA nod, 8 years after stinging rejection

In two pivotal studies years apart, Aveo Oncology’s drug tivozanib did not help kidney cancer patients live longer overall compared to the standard of care. The FDA approved still approved it, the latest development in a long saga that includes several regulatory stumbles.

Are Lectins in Food Good or Bad for You?

Might lectins help explain why those who eat more beans and whole grains have less cancer? Lectins are to blame for the great “white kidney bean incident” of 2006 in Japan. One Saturday evening, a TV program introduced a new method to lose weight. The method was simple: toast some dry, raw, white kidney beans …

Are Lectins in Food Good or Bad for You? Read More »

Takeda buys Maverick as T-Cell engager research hots up

Takeda is taking its option to buy the privately held biotech Maverick Therapeutics and its T-Cell engager cancer therapies for $525 million, as research into the technology gathers pace. San Francisco-based Maverick’s technology is designed to target solid tumours with a T-cell attack that focuses on cancerous tissues while leaving healthy tissue alone. Standard T-cell …

Takeda buys Maverick as T-Cell engager research hots up Read More »

How to Avoid Lectin Poisoning

How should we properly cook beans? In the 1800s, a compound was discovered in castor beans, which we would come to know as the first of a class of lectin proteins, natural compounds found throughout the food supply, but concentrated in beans, whole grains, and certain fruits and vegetables. Every decade or two, a question …

How to Avoid Lectin Poisoning Read More »

Roche’s Tecentriq loses bladder cancer use as FDA crackdown continues

Roche’s Tecentriq is the latest medicine to fall foul of a crackdown by the FDA on drugs that have failed to live up to their early promise. The Swiss pharma said it is voluntarily withdrawing the US indication for the immunotherapy Tecentriq (atezolizumab) in metastatic urothelial carcinoma (mUC) previously treated with chemotherapy. As with AstraZeneca’s …

Roche’s Tecentriq loses bladder cancer use as FDA crackdown continues Read More »

Novartis’ canakinumab falls short in phase 3 lung cancer trial

Novartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless a disappointing feeling when things don’t work out. Already approved for auto-inflammatory diseases such as active systemic juvenile idiopathic arthritis under the brand name Ilaris, Novartis is testing canakinumab to see if inhibiting the IL-1beta pathway can …

Novartis’ canakinumab falls short in phase 3 lung cancer trial Read More »

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against standard non-small cell lung cancer, NSCLC, yet in addition against the KRAS-mutant malignancy which seems, by all accounts, aggressive, barely accessible by chemotherapy and very normal (thirty percent of total cases of NSCLS) in people. …

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy Read More »

Roche to Withdraw Tecentriq Indication in Metastatic Bladder Cancer in the US

Shots: The company reported the voluntary withdrawal of the Tecentriq (atezolizumab) indication in the US for prior-platinum treated mUC, bladder cancer The withdrawal was made in consultation with the US FDA to review the accelerated approvals with confirmatory trials that have not met 1EPs and have yet to gain regular approvals. The decision does not …

Roche to Withdraw Tecentriq Indication in Metastatic Bladder Cancer in the US Read More »

BioIntelliSense Partners with Leukemia & Lymphoma Society for Continuous Monitoring in Clinical Trials

What You Should Know: –BioIntelliSense announced it has entered into a strategic partnership with The Leukemia & Lymphoma Society (LLS) to incorporate the BioSticker™ platform in clinical trials of hematological cancer patients. – The LLS clinical trials will include use of the BioSticker medical device for the continuous collection of vital sign and physiological data …

BioIntelliSense Partners with Leukemia & Lymphoma Society for Continuous Monitoring in Clinical Trials Read More »

Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease

Jon Gingrich, CEO, Echosens North America Leveraging technological advances to facilitate new ways of engaging patients and integrating non-invasive technology into a liver disease program not only serves to improve individual outcomes and reduce costs but also strengthens the financial performance of health systems and provider organizations that include this approach to testing. At a …

Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease Read More »

Amgen in $1.9bn swoop for Five Prime and its gastric cancer drug

Amgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer drug to its pipeline. The big pharma swooped in after the California biotech reported promising phase 2 trial results from bemarituzumab in November. The phase 2 FIGHT trial testing bemarituzumab plus chemotherapy as a front-line therapy for advanced gastric …

Amgen in $1.9bn swoop for Five Prime and its gastric cancer drug Read More »

Agilent to Acquire Resolution Bioscience for $695M

Shots: Resolution to receive $550M in cash at closing and ~$145M following the achievement of certain milestones. The transaction is expected to close in Apr’2021 The acquisition will expand Agilent’s capabilities in NGS-based cancer diagnostics and strengthen its position in precision oncology testing globally The acquisition will bring together Resolution’s noninvasive liquid biopsy platform that …

Agilent to Acquire Resolution Bioscience for $695M Read More »

Dr. Gundry’s The Plant Paradox Is Wrong

A book purported to expose “hidden dangers” in healthy foods doesn’t even pass the whiff test. I started getting emails about The Plant Paradox, a book purporting to expose “the hidden dangers in ‘healthy’ foods that cause disease and weight gain”—foods like beans, whole grains, and tomatoes. Hidden dangers? The author’s talking about lectins in …

Dr. Gundry’s The Plant Paradox Is Wrong Read More »

How digital health impacts the development and adoption of cancer immunotherapies [Sponsored]

In an interview, BrightInsight Co-founder and CEO Kal Patel, MD, offered a preview of the report, The Role of Digital Health in Immuno-oncology Therapy Development and Adoption.

Merck & Co axes Keytruda lung cancer niche amid FDA crackdown

Merck & Co has voluntarily withdrawn its Keytruda immunotherapy from a lung cancer niche in the US, amid a crackdown by the FDA on drugs approved without the required post-marketing data. Keytruda had been granted accelerated approval in metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least …

Merck & Co axes Keytruda lung cancer niche amid FDA crackdown Read More »

Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair?

With covid vaccines expected to remain scarce into early spring, Connecticut has scrapped its complicated plans to prioritize immunizations for people under 65 with certain chronic conditions and front-line workers. Instead, the state will primarily base eligibility on age. Gov. Ned Lamont pointed to statistics showing the risk of death and hospitalization from covid-19 rises …

Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair? Read More »

NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final draft guidance, NICE recommended Kiskali be taken out of the Cancer Drugs Fund, which has been providing interim reimbursement since 2019 until further trial data emerged addressing uncertainties about overall …

NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali Read More »

FDA to quickly review Incyte’s Jakafi in chronic GVHD

The FDA is to begin a fast review of Incyte’s Jakafi (ruxolitinib) for patients with chronic graft-versus-host disease (GVHD), which cannot be treated with steroids. The US pharma, which has partnered with Novartis to develop this first-in-class JAK1/JAK2 inhibitor, said the FDA will review data from the phase 3 REACH 3 study comparing Jakafi to …

FDA to quickly review Incyte’s Jakafi in chronic GVHD Read More »

Sanofi’s immunotherapy Libtayo gets FDA not in first line lung cancer

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer, in non-small cell lung cancer patients whose tumours have high PD-L1 expression brings the drug into competition with Merck & Co’s Keytruda (pembrolizumab), which has become the go-to …

Sanofi’s immunotherapy Libtayo gets FDA not in first line lung cancer Read More »

Limited access to cancer biomarker testing in Europe, report finds

There is limited access to biomarker testing for cancer in Europe, despite the huge potential of the technology to improve outcomes, according to a new report. The report from European Federation of Pharmaceutical Industries and Associations (EFPIA) shows the results of research conducted in 2020 to assess the availability, quality and reimbursement of biomarker tests …

Limited access to cancer biomarker testing in Europe, report finds Read More »

Zynteglo halt re-ignites viral vector safety concerns; analysts

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface.  That’s the view of analysts at Jefferies, who suggest it could “re-ignite concerns over the …

Zynteglo halt re-ignites viral vector safety concerns; analysts Read More »

AZ withdraws Imfinzi in US bladder cancer use after trial failure

AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab) in a bladder cancer indication in the US. AZ’s share price ticked downwards after the announcement that it will stop marketing Imfinzi, a PD-L1 class immunotherapy, for previously treated adult patients with advanced or metastatic bladder cancer. It’s news that will …

AZ withdraws Imfinzi in US bladder cancer use after trial failure Read More »

Astellas/Seagen prepare full US filing of bladder cancer drug Padcev

Astellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev in the US, based on trial results announced over the weekend. To recap, Padcev (enfortumab vedotin) was quickly okayed by the FDA in December 2019 in advanced urothelial cancer on the basis of phase 2 response data …

Astellas/Seagen prepare full US filing of bladder cancer drug Padcev Read More »

BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

Shots: MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory and sales milestone along with royalties on future sales MTEM will be responsible for research activities to discover next generation ETBs for multiple targets, of which BMS selected the first target. BMS to get an option to obtain …

BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer Read More »

Does Nutritional Yeast Trigger Crohn’s Disease?

Is the exaggerated reaction of many Crohn’s disease patients to baker’s, brewer’s, and nutritional yeast just a consequence of their inflamed leaky gut, or might the yeast be a contributing cause? “Baker’s Yeast in Crohn’s Disease—Can It Kill You?” is the inflammatory title (no pun intended) of a 1999 journal article. Crohn’s disease is an …

Does Nutritional Yeast Trigger Crohn’s Disease? Read More »

Seagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancer

Seagen and Genmab have announced they have filed their antibody-drug conjugate tisotumab vedotin with the FDA for patients with recurrent or metastatic cervical cancer. The companies are asking for an accelerated approval based on phase 2 data, which will have to be confirmed by data from a larger trial that will provide survival data. The …

Seagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancer Read More »

Health Plans Must Go Beyond the ONC Mandate and Prioritize Member Experience

Minal Patel, CEO of Abacus Insights Laurent Rotival, SVP, Strategic Technology Solutions & CIO, Cambia Solutions We are all frustrated when there’s a glitch with our online banking, or if bandwidth problems interfere with streaming the movie we want to watch. Imagine how individuals will react when the results of a cancer screening don’t find …

Health Plans Must Go Beyond the ONC Mandate and Prioritize Member Experience Read More »

A study to avoid chemotherapy in patients with early HER-2+ breast cancer

MEDSIR, a global company dedicated to independent clinical research in oncology, has initiated the PHERGain II clinical trial to demonstrate that in patients with HER2-positive early breast cancer with a good prognosis, a chemotherapy-free therapeutic approach can be as effective as the current standard of care, which involves the use of this generally more toxic …

A study to avoid chemotherapy in patients with early HER-2+ breast cancer Read More »

Why Cancer Registries are Part of America’s Fight for Racial Equality

Warren A Whyte, Ph.D., VP Scientific Partnerships at ConcertAI According to a 2019 study in the Proceedings of the National Academy of Sciences, one in 1,000 Black males can expect to die at the hands of the police. Black males were also 2.5 times more likely to die during an encounter with police than white …

Why Cancer Registries are Part of America’s Fight for Racial Equality Read More »

Gene Screenings Hold Disease Clues, but Unexplained Anomalies Often Raise Fears

When her gynecologist recommended genetic testing, Mai Tran was reluctant. “I didn’t really want to do it,” recalled Tran, who had just turned 21 and was living in New York City, “but she kept on emailing me about it and was really adamant that I do it.” Tran knew she had an elevated risk of …

Gene Screenings Hold Disease Clues, but Unexplained Anomalies Often Raise Fears Read More »

Executive Hires: Walgreens Appoints New CEO, Cityblock Health, Innovaccer, Others

Walgreens appoints Rosalind (Roz) Brewer as the company’s Chief Executive Officer, effective on March 15, 2021. Brewer will also join the WBA Board of Directors upon assuming the role. She succeeds Stefano Pessina who, as previously announced, will transition to the role of Executive Chairman of the Board of WBA. Brewer, 58, will become the …

Executive Hires: Walgreens Appoints New CEO, Cityblock Health, Innovaccer, Others Read More »

Treating Advanced Prostate Cancer with Diet

Dr. Dean Ornish showed that a plant-based diet and lifestyle program could apparently reverse the progression of prostate cancer for early stage, localized, watch-and-wait cancer. What about for more advanced stage life-threatening disease? Dr. Dean Ornish showed that a plant-based diet and lifestyle program could apparently reverse the progression of prostate cancer by making men’s …

Treating Advanced Prostate Cancer with Diet Read More »

Action needed to preserve the six protected classes

In the final hours of the previous Administration’s time in office, the Center for Medicare & Medicaid Innovation (the Innovation Center) (CMMI) announced new changes for CY 2022 to an existing five-year Part D Payment Modernization Model. This model would provide “formulary flexibility” by exempting Part D plans in the Model from some of Part …

Action needed to preserve the six protected classes Read More »

A Patient Engagement Strategy Needs to Deliver a Holistic Experience

Chris Evanguelidi, Director, Enterprise Healthcare Market for Redpoint Global Inc. Researchers from Johns Hopkins published a study in October on the impact of the pandemic on health care delivery. Among its findings, the data show a 21.4% decrease in primary care visits in Q2 of 2020, compared against the average volume of Q2 visits for …

A Patient Engagement Strategy Needs to Deliver a Holistic Experience Read More »

Syapse Lands $68M to Expand Global Precision Oncology Data Sharing Network

What You Should Know: – Syapse raises 68M in equity investment  led by Ally Bridge Group (ABG), with Northpond Ventures to expand delivery of real-world evidence  through Syapse’s Learning Health Network. – The Syapse Learning Health Network is a global precision oncology data sharing network, improving cancer care across communities by using real-world data to …

Syapse Lands $68M to Expand Global Precision Oncology Data Sharing Network Read More »

Volpara Acquires Breast Cancer Risk Assessment Platform CRA Health for $18M

What You Should Know: –  Volpara Health, an integrated breast care platform assisting in the delivery of personalized patient care has acquired breast cancer risk assessment platform CRA Health. – CRA Health, LLC, is a breast cancer risk assessment company spinoff from Massachusetts General Hospital — a Harvard Medical School teaching hospital. Today the company delivers more …

Volpara Acquires Breast Cancer Risk Assessment Platform CRA Health for $18M Read More »

AZ/Daiichi Sankyo’s partnership makes progress in lung cancer

AstraZeneca and Daiichi Sankyo have announced data from two drugs in lung cancer, which they are developing as part of their ongoing partnership. Results announced at the World Conference on Lung Cancer came from Enhertu (trastuzumab deruxtecan), which targets cancers expressing the HER2 receptor and is already approved in certain lung and bladder cancers expressing …

AZ/Daiichi Sankyo’s partnership makes progress in lung cancer Read More »

Coconut Oil and the Boost in HDL “Good” Cholesterol

The effects of coconut oil were compared to butter and tallow. Even if virgin coconut oil and other saturated fats raise LDL “bad” cholesterol, isn’t that countered by the increase in HDL “good” cholesterol? According to “the experience and wisdom of 200 of the country’s leading experts in cardiovascular diseases,” in a report representing 29 …

Coconut Oil and the Boost in HDL “Good” Cholesterol Read More »

If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine?

As public demand grows for limited supplies of covid-19 vaccines, questions remain about the vaccines’ appropriateness for older adults with various illnesses. Among them are cancer patients receiving active treatment, dementia patients near the end of their lives and people with autoimmune conditions. Recently, a number of readers have asked me whether older relatives with …

If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? Read More »

Pandemic ‘pushed lung cancer services back 20 years’, doctors warn

Governments must act to restore the damage done to lung cancer services during the pandemic in order to reduce further avoidable deaths, according to a report drawn up as part of this week’s World Economic Forum in Davos. The report, Learning Lessons from Across Europe – Prioritising Lung Cancer after COVID-19, highlights how lung cancer …

Pandemic ‘pushed lung cancer services back 20 years’, doctors warn Read More »

Careology joins forces with remote care support firm RedArc

Digital cancer care platform Careology has joined forces with RedArc, which provides long-term support for people with serious illnesses. RedArc has a team of registered nurses that provide support and expert advice by phone to people after referral from insurers, trade unions and groups such as trade unions. The new partnership provides RedArc nurses with …

Careology joins forces with remote care support firm RedArc Read More »

To Beat COVID-19, We Need A Modern Approach to Public Health Data

Ed Simcox, Chief Strategy Officer at LifeOmic The COVID-19 pandemic, which has taken 270,000 American lives to date, has shined a light on another crisis — the U.S. currently has no standardized system for reporting public health data. Health departments all over the country resort to using paper, fax, phone, and email to transmit and …

To Beat COVID-19, We Need A Modern Approach to Public Health Data Read More »

ICYMI: Cancer death rate continues decline due to advances in treatment

For the second year in a row, The American Cancer Society (ACS) reports a record single-year decline in cancer death rates in the United States. Each year, ACS estimates the number of new cancer cases and deaths that will occur in the United States. For nearly 30 years, the trend towards fewer cancer deaths has …

ICYMI: Cancer death rate continues decline due to advances in treatment Read More »

Do the Pros of Brown Rice Outweigh the Cons of Arsenic?

Are there unique benefits to brown rice that would justify keeping it in our diet despite the arsenic content? For years, warnings had been given about the arsenic levels in U.S. rice potentially increasing cancer risk, but it had never been put to the test until a study out of Harvard. The finding? “Long-term consumption …

Do the Pros of Brown Rice Outweigh the Cons of Arsenic? Read More »

AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication

AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach cancer and haven’t responded to Roche’s Herceptin (trastuzumab). This latest indication adds to Enhertu first approval at the end of 2019 for advanced HER2-positive breast cancer after two or more HER2-targeted regimens. Around one in five gastric …

AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication Read More »

Ex-Merck & Co scientist accused of stealing trade secrets could face jail

A former Merck & Co scientist could face up to 10 years in prison after he was accused of stealing trade secrets relating to drugs including the cancer immunotherapy Keytruda by US authorities. In a document outlining the charges against Shafat Quadri, of North Potomac, Maryland the US Department of Justice (DoJ) referred only to …

Ex-Merck & Co scientist accused of stealing trade secrets could face jail Read More »

FCC Unveils 14 Initial Projects Selected for $100M Connected Care Pilot Program

What You Should Know: – FCC announces initial 14 pilot project selected for $100M Connected Care Pilot Program that will support connected care service across the country and focus on low-income and veteran patients. The Federal Communications Commission (FCC) today announced an initial set of 14 pilot projects with over 150 treatment sites in 11 …

FCC Unveils 14 Initial Projects Selected for $100M Connected Care Pilot Program Read More »

NICE recommends interim funding for GSK’s Zejula in ovarian cancer

Women with newly-diagnosed advanced ovarian cancer have a new treatment option in England after NICE recommend interim funding for GlaxoSmithKline’s Zejula (niraparib) in final guidance. Zejula competes with AstraZeneca/Merck & Co’s PARP inhibitor class rival Lynparza (olaparib) but in this case it has an advantage in this maintenance therapy use as it can be used …

NICE recommends interim funding for GSK’s Zejula in ovarian cancer Read More »

Is White Rice a Yellow-Light or Red-Light Food?

Arsenic is not just considered to be a carcinogen; it’s also designated as a “nonthreshold carcinogen, meaning that any dose, no matter how small, carries some cancer risk”—so there really isn’t a “safe” level of exposure. Given that, it may be reasonable to “use the conservative ALARA” approach, reducing exposure As Low As Reasonably Achievable. …

Is White Rice a Yellow-Light or Red-Light Food? Read More »

Boehringer to investigate ‘dark antigens’ with UK cancer specialist Enara

Boehringer Ingelheim has signed a strategic collaboration with UK biotech Enara Bio, focused on finding ways to fight cancer using “dark antigens” in a deal worth up to €876 million ($1.07bn). Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic “dark matter” – the portion of the human genome that …

Boehringer to investigate ‘dark antigens’ with UK cancer specialist Enara Read More »

How Much Arsenic in Rice Is Too Much?

What are some strategies to reduce arsenic exposure from rice? Those who are exposed to the most arsenic in rice are those who are exposed to the most rice, like people who are eating plant-based, gluten-free, or dairy-free. So, at-risk populations are not just infants and pregnant women, but also those who may tend to …

How Much Arsenic in Rice Is Too Much? Read More »

Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off

Medivir, IGM Biosciences enters into an exclusive licensing agreement for Birinapant Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. Birinapant is a clinical-stage SMAC mimetic that degrades Inhibitors of Apoptosis Proteins (IAPs) by binding to them, ultimately leading to cell death in tumor …

Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off Read More »

AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer

Shots: The companies collaborated to evaluate the use of immunoSEQ T-MAP, for which Adaptive will receive quarterly payments + sequencing and data mapping fees AstraZeneca to provide cancer patients’ biological samples while Adaptive will sequence the samples & deliver TCR-antigen mapping data using its clinical immunomics database of 58B+ immune cell receptors and antigens AstraZeneca …

AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer Read More »

COVID-19 Deferrals Lead to 3 Major Conditions Payers/Providers Must Address in 2021

What You Should Know: – COVID-19 care deferrals lead to three major boomerang conditions that payers and providers must proactively address in 2021, according to a newly released report by Prealize. – COVID-19’s hidden victims—those who avoided or deferred care during the pandemic—will increasingly return to the healthcare system, and many will be diagnosed with …

COVID-19 Deferrals Lead to 3 Major Conditions Payers/Providers Must Address in 2021 Read More »

How Risky Is the Arsenic in Rice?

Getting rice down to the so-called safe water limit for arsenic would still allow for roughly 500 times greater cancer risk than is normally considered acceptable. Given the level of arsenic in rice, how could we figure out how much rice is too much? There are no U.S. standards for arsenic in rice, even though …

How Risky Is the Arsenic in Rice? Read More »

Pfizer deal paves way for approval of ImaginAb’s cancer imaging tech

ImaginAb has signed a deal with Pfizer, which it hopes will help it to gather information necessary for approval of its tumour imaging agent as a medical device in markets in the US and other countries. The California-based company has signed a non-exclusive license with Pfizer to supply its 89Zr CD8 Immuno-PET agent, which can …

Pfizer deal paves way for approval of ImaginAb’s cancer imaging tech Read More »

Why cell therapy manufacture is a team sport

Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that sits behind the process of individualised cell therapy – and why team culture makes it work This thought leadership series has been paid and developed by Kite, a Gilead Company. In 2018, we were preparing to build …

Why cell therapy manufacture is a team sport Read More »